Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Arena Pharmaceuticals, Inc.    ARNA

Delayed Quote. Delayed  - 07/25 10:00:00 pm
1.66 USD   -1.19%
07/19 EISAI : Inc. and Arena Pharmaceuticals Announce FDA Approval of BELV..
07/14 ARENA PHARMACEU : Eisai and Arena Pharmaceuticals Announce Regulator..
06/30 ARENA PHARMACEU : Announces Shift to Focus on Proprietary Clinical S..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Arena Pharmaceuticals, Inc. : Five Star Equities Issues New Research Reports on ARNA, DD, KR and VECO

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/17/2013 | 03:05pm CEST

Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares hit a low of $7.70 Friday before settling to close at $7.78, a decrease of 6.71 percent. The stock traded in between $7.70 to $8.30 on volume of 8.97 million shares traded. Consumer Reports has recently advised their readers to ?skip? Arena?s weight loss drug, Belviq.

Get more information on Arena Pharmaceuticals and free access to the in-depth equity report at:
www.FiveStarEquities.com/ARNA

E I Du Pont De Nemours And Co (NYSE: DD) shares hit a low of $52.16 Friday before settling to close at $52.68, a decrease of 2.23 percent. The stock traded in between $52.16 to $53.70 on volume of 11.28 million shares traded. Jefferies Group currently has a ?hold? rating on the stock and has recently raised its price target on the company to $56.00 from $52.00.

Get more information on Du Pont and free access to the in-depth equity report at:
www.FiveStarEquities.com/DD

The Kroger Co. (NYSE: KR) hit a low of $34.67 Friday before settling to close at $34.79, a decrease of 0.77 percent. The stock traded in between $34.67 to $35.25 on volume of 2.46 million shares traded. Argus currently has a ?buy? rating on the stock and has recently raised its price target on the company to $40.00 from $34.00.

Get more information on Kroger and free access to the in-depth equity report at:
www.FiveStarEquities.com/KR

Veeco Instruments Inc. (NASDAQ: VECO) shares hit a low of $37.74 Friday before settling to close at $38.10, a decrease of 3.20 percent. The stock traded in between $37.74 and $39.04 on volume of 559,990 shares traded. UBS has reiterated it ?neutral? view on the company due to pricing pressure pricing pressure Veeco?s metal organic vapor deposition epitaxial systems.

Get more information on Veeco Instruments and free access to the in-depth equity report at:
www.FiveStarEquities.com/VECO

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Five Star Equities
info@fivestarequities.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ARENA PHARMACEUTICALS, INC
07/19 ARENA PHARMACEUTICALS INC : Other Events (form 8-K)
07/19 EISAI : Inc. and Arena Pharmaceuticals Announce FDA Approval of BELVIQ XR® (lorc..
07/14 ARENA PHARMACEUTICALS : Eisai and Arena Pharmaceuticals Announce Regulatory Appr..
07/07 ARENA PHARMACEUTICALS : Announces Shift to Focus on Proprietary Clinical Stage P..
06/30 ARENA PHARMACEUTICALS INC : Costs Associated with Exit or Disposal Activities (f..
06/30 ARENA PHARMACEUTICALS : Announces Shift to Focus on Proprietary Clinical Stage P..
06/23 ARENA PHARMACEUTICALS : Announces USAN Approval of Nonproprietary Name "Etrasimo..
06/23 ARENA PHARMACEUTICALS : Announces Appointment of Kevin R. Lind as Chief Financia..
06/16 ARENA PHARMACEUTICALS : Announces Appointment of Kevin R. Lind as Chief Financia..
06/16 ARENA PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financial..
More news
Sector news : Biotechnology & Medical Research - NEC
12:45a GILEAD SCIENCES : cuts 2016 sales forecast, cites hepatitis C drugs
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- 2nd Update
07/25DJCELGENE : Drug Misses Secondary Endpoint in One of Its Lymphoma Trials
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- 3rd Update
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- Update
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
07/21 The End Of Another Chapter In Obesity Drug Development
07/20 Vivus Begins Q3 With Underwhelming Qsymia Sales
07/20 What Arena's Recent FDA Approval Means For The Future
07/20 Orexigen - Contrave Scripts Nosedive With Holiday Week - Downward Pressure Ta..
07/19 Arena - Belviq Scripts Start Q3 In Tough Shape
Advertisement
Financials ($)
Sales 2016 48,7 M
EBIT 2016 -79,7 M
Net income 2016 -83,1 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 8,28x
Capi. / Sales 2017 5,99x
Capitalization 403 M
More Financials
Chart ARENA PHARMACEUTICALS, INC
Duration : Period :
Arena Pharmaceuticals, Inc Technical Analysis Chart | ARNA | US0400471027 | 4-Traders
Full-screen chart
Technical analysis trends ARENA PHARMACEUTI...
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 6
Average target price 3,75 $
Spread / Average Target 126%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Amit D. Munshi President, Chief Executive Officer & Director
Craig M. Audet SVP-Operations & Head-Global Regulatory Affairs
Kevin R. Lind Chief Financial Officer & Executive Vice President
Dominic P. Behan Executive Director, Chief Scientific Officer & EVP
Donald D. Belcher Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ARENA PHARMACEUTICALS,..-12.63%403
INCYTE CORPORATION-20.30%16 216
CELLTRION, INC.--.--%10 681
LONZA GROUP AG11.40%9 730
QUINTILES TRANSNATIONA..7.89%8 865
ALKERMES PLC-36.86%7 576
More Results